Vor Biopharma has developed a CRISPR-augmented stem cell transplant called trem-cel, which protects healthy cells from the toxic effects of anti-cancer medicines. In a study involving patients with high-risk acute myeloid leukemia, eight out of 10 patients remained in remission after receiving the Vor therapy followed by intensified doses of Mylotarg. This combination treatment was effective in delaying relapse and was well-tolerated with no severe side effects reported. The results suggest that trem-cel could be a promising treatment option for leukemia patients, offering a potential way to improve outcomes and reduce toxicity associated with existing treatments.
Source link
Vor Biopharma’s ‘shielded’ transplant delays relapse in leukemia patients
